^
Association details:
Biomarker:TP53 mutation
Cancer:Acute Myelogenous Leukemia
Drug:A-1331852 (Bcl-xL inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

CL-2/BCL-XL INHIBITION INDUCES APOPTOSIS AND CIRCUMVENTS VENETOCLAX RESISTANCE IN TP53-MUTATED ACUTE MYELOID LEUKEMIA

Published date:
05/11/2023
Excerpt:
In contrast, TP53mut patients (n=12/109) had increased sensitivity to A-1331852 (Figure A), and the dual BCL-2/BCL-XL inhibitor navitoclax was highly effective in TP53mut blasts when compared to single agents venetoclax and A-1331852 (Figure B).
Trial ID: